Phase III study of Baricitinib in patients with moderate-to-severe Atopic Dermatitis.
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 18 Sep 2017 New trial record
- 14 Sep 2017 According to an Eli Lilly media release, the company is planning to initiate Phase 3 clinical program later this year.